FY2025 · ended Dec 31, 2025 · Revenue $36.97M, +17.8% YoY · Filed Mar 17, 2026
ClearPoint Neuro, Inc. (CLPT) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $37.0 million and a net loss of $25.5 million. Free cash flow was -$24.4 million. As of Sep 30, 2026 it held $46.2 million in cash and investments and $73.7 million in total debt.
Revenue (TTM)
$45.49M
+32.5% vs year-ago TTM
Net income (TTM)
$-36.13M
-56.2% vs year-ago TTM
Operating cash flow (TTM)
$-32.15M
-145.6% vs year-ago TTM
Free cash flow (TTM)
$-33.19M
-140.1% vs year-ago TTM
EPS (TTM)
$-1.21
-46.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
29.66M
+7.4% vs prior year
Net cash
$-27.52M
as of Sep 30, 2026
Operating margin
-70.6%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CLPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1285550
- Former names
- MRI INTERVENTIONS, INC. (until Feb 11, 2020); SURGIVISION INC (until Oct 22, 2010); SURGI VISION INC (until May 2, 2007)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M | -$13.4M |
| Net income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M |
| Diluted EPS | -$0.90 | -$0.70 | -$0.90 | -$0.68 | — |
| Operating cash flow | -$23.9M | -$8.9M | -$13.7M | -$16.2M | -$12.7M |
| Free cash flow | -$24.4M | -$9.2M | -$14.4M | -$16.4M | -$12.9M |
| Total assets | $97.7M | $39.2M | $42.7M | $55.5M | $65.6M |
| Total liabilities | $69.7M | $13.8M | $21.5M | $18.6M | $16.8M |
| Stockholders' equity | $28.0M | $25.4M | $21.2M | $36.9M | $48.8M |
| Cash and investments | $45.9M | $20.1M | $23.1M | $37.5M | $54.1M |
| Total debt | $58.2M | $3.6M | $13.9M | $12.0M | $12.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 1006 ClearPoint Neuro, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.